Literature DB >> 258162

Specific induction of pulmonary indoleamine 2,3-dioxygenase by bacterial lipopolysaccharide.

O Hayaishi, R Yoshida.   

Abstract

Indoleamine 2,3-dioxygenase (molecular weight about 42,000) has been purified from rabbit intestines and contains one mole of protohaem IX as the sole prosthetic group. It catalyses the oxidative cleavage of the pyrrole ring of various indoleamines with a much broader specificity of substrate than tryptophan 2,3-dioxygenase. The enzyme has an absolute requirement for superoxide anion for catalytic activity. The enzyme was induced specifically in the lungs of mice for 24 h after administration of the lipopolysaccharide fraction of E. coli. This increase is due to synthesis of enzyme protein and is specific for the lipopolysaccharide fraction. These results are interpreted to mean that indoleamine dioxygenase is induced in pulmonary inflammatory processes in response to an increase in production of superoxide anion, 5-hydroxytryptamine or other indoleamines in the lung as a consequence of inflammation. The dioxygenase reaction is a more innocuous way of disposing of superoxide than dismutation.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 258162     DOI: 10.1002/9780470715413.ch12

Source DB:  PubMed          Journal:  Ciba Found Symp        ISSN: 0300-5208


  8 in total

1.  Induction of indoleamine-2,3 dioxygenase in bone marrow stromal cells inhibits myeloma cell growth.

Authors:  Sabine Pfeifer; Martin Schreder; Arnold Bolomsky; Sebastian Graffi; Dietmar Fuchs; Surinder S Sahota; Heinz Ludwig; Niklas Zojer
Journal:  J Cancer Res Clin Oncol       Date:  2012-06-22       Impact factor: 4.553

Review 2.  Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences.

Authors:  Diwakar Davar; Nathan Bahary
Journal:  Target Oncol       Date:  2018-04       Impact factor: 4.493

Review 3.  Trial watch: IDO inhibitors in cancer therapy.

Authors:  Erika Vacchelli; Fernando Aranda; Alexander Eggermont; Catherine Sautès-Fridman; Eric Tartour; Eugene P Kennedy; Michael Platten; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-15       Impact factor: 8.110

4.  Kynurenine pathway metabolites in humans: disease and healthy States.

Authors:  Yiquan Chen; Gilles J Guillemin
Journal:  Int J Tryptophan Res       Date:  2009-01-08

5.  Antibodies to quinolinic acid and the determination of its cellular distribution within the rat immune system.

Authors:  J R Moffett; M G Espey; M A Namboodiri
Journal:  Cell Tissue Res       Date:  1994-12       Impact factor: 5.249

6.  Twin study shows association between monocyte chemoattractant protein-1 and kynurenic acid in cerebrospinal fluid.

Authors:  Viktoria Johansson; Sophie Erhardt; Göran Engberg; Magdalena Kegel; Maria Bhat; Lilly Schwieler; Kaj Blennow; Henrik Zetterberg; Tyrone D Cannon; Lennart Wetterberg; Christina M Hultman; Mikael Landén
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-07-13       Impact factor: 5.270

7.  Decreased protein nitration in macrophages that overexpress indoleamine 2, 3-dioxygenase.

Authors:  Derin B Keskin; Brendan Marshall; David Munn; Andrew L Mellor; Debra A Gearhart
Journal:  Cell Mol Biol Lett       Date:  2006-11-13       Impact factor: 5.787

8.  Targeting Tregs in Malignant Brain Cancer: Overcoming IDO.

Authors:  Derek A Wainwright; Mahua Dey; Alan Chang; Maciej S Lesniak
Journal:  Front Immunol       Date:  2013-05-15       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.